
Discover Âé¶¹¹ú²úAV
Same Company, Different Operating System: Carlos’ Neurodiverse Journey

Access & Impact
Âé¶¹¹ú²úAV Publishes 2024 Sustainability Report: Building Sustainable Access at Scale

Discover Âé¶¹¹ú²úAV
Âé¶¹¹ú²úAV Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Discover Âé¶¹¹ú²úAV